Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials

• Published in: Atherosclerosis Vol. 223; no. 2; pp. 251 - 261
• Main Authors: Morrone, Doralisa, Weintraub, William S., Toth, Peter P., Hanson, Mary E., Lowe, Robert S., Lin, Jianxin, Shah, Arvind K., Tershakovec, Andrew M.
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Ireland Ltd 01.08.2012; Elsevier
• Subjects: adults; adverse effects; Aged; Anticholesteremic Agents; Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - therapeutic use; atherosclerosis; Atherosclerosis (general aspects, experimental research); Azetidines; Azetidines - adverse effects; Azetidines - therapeutic use; Biological and medical sciences; Biomarkers; Biomarkers - blood; blood; Blood and lymphatic vessels; Cardiology. Vascular system; Cardiovascular; cholesterol; Cholesterol, LDL; Cholesterol, LDL - blood; clinical trials; Clinical Trials as Topic; diabetes mellitus; drug therapy; Drug Therapy, Combination; Evidence-Based Medicine; Ezetimibe; Female; gender; General and cellular metabolism. Vitamins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia; Hypercholesterolemia - blood; Hypercholesterolemia - drug therapy; low density lipoprotein; Male; Medical sciences; Middle Aged; patients; Pharmacology. Drug treatments; risk; Statin; therapeutic use; therapeutics; Treatment Outcome; triacylglycerols; Hypercholesterolemia; Ezetimibe; Statin; Human; Metabolic diseases; Lipids; Cardiovascular disease; Hyperlipoproteinemia; Statin derivative; Lipoprotein; Cholesterol; Vascular disease; Treatment; Atherosclerosis; Dyslipemia; Antilipemic agent

Patients with dyslipoproteinemia constitute the largest risk group for development of atherosclerosis and cardiovascular disease (CVD). Despite extensive statin use, many patients with CVD risk do not achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets. This pooled anal...